In the last week, the United States market has been flat, yet it has shown significant strength over the past year with a 37% increase and earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in alignment with these robust market conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

GDS Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: GDS Holdings Limited, along with its subsidiaries, focuses on developing and operating data centers in China, with a market capitalization of approximately $4.32 billion.

Operations: GDS Holdings generates revenue primarily through the design, build-out, and operation of data centers in China, with this segment contributing CN¥10.53 billion. The company's focus on data center operations underlines its role in supporting digital infrastructure needs in the region.

GDS Holdings, while navigating a challenging landscape with a net loss reported in its recent earnings, shows promise with an expected revenue growth of 15% per year, outpacing the US market average of 8.8%. This growth is underpinned by strategic expansions and investments in technology infrastructure. Notably, GDS's commitment to enhancing its service offerings is evident from its R&D expenses which are crucial for maintaining competitive edge in the rapidly evolving tech sector. Despite current unprofitability and shareholder dilution over the past year, projections indicate GDS could turn profitable within three years, suggesting potential for future stabilization and growth.

• Click here to discover the nuances of GDS Holdings with our detailed analytical health report.

• Learn about GDS Holdings' historical performance.

Alkami Technology

Simply Wall St Growth Rating: ★★★★★☆

Overview: Alkami Technology, Inc. provides cloud-based digital banking solutions in the United States and has a market capitalization of approximately $3.78 billion.

Operations: Alkami specializes in cloud-based digital banking solutions, generating revenue primarily from its Internet Software & Services segment, which amounts to $297.36 million.

Alkami Technology, despite a challenging financial landscape marked by a net loss of $12.32 million in Q2 2024, is making significant strides with its digital banking platform, evidenced by recent partnerships with Nutmeg State and Intrepid Credit Unions. These collaborations highlight Alkami's commitment to enhancing user experiences and expanding service capabilities, crucial in the competitive fintech space. With R&D expenses reflecting a proactive approach to innovation—critical for staying ahead in technology-driven markets—Alkami's revenue growth forecast at 21.4% annually outpaces the broader US market projection of 8.8%. This growth trajectory is supported by strategic client engagements and product enhancements that cater to evolving consumer needs in digital banking, setting a robust foundation for potential profitability within three years as earnings are expected to surge by 98.5% annually.

• Click to explore a detailed breakdown of our findings in Alkami Technology's health report.

• Assess Alkami Technology's past performance with our detailed historical performance reports.

BioCryst Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing oral small-molecule and protein therapeutics for the treatment of rare diseases, with a market cap of approximately $1.56 billion.

Operations: BioCryst Pharmaceuticals generates revenue primarily from its biotechnology segment, amounting to $382.24 million. The company focuses on developing oral small-molecule and protein therapeutics for rare diseases.

BioCryst Pharmaceuticals is navigating a transformative phase with its focus on rare diseases, notably through ORLADEYO®, a treatment for hereditary angioedema that's reducing hospital visits and emergency room usage significantly. This innovation underpins their R&D commitment, where expenses are keenly allocated to foster groundbreaking therapies. Notably, the company's revenue is projected to grow at 15.5% annually, outpacing the broader market's 8.8%. Moreover, earnings are expected to surge by an impressive 70.5% per year, reflecting both the potential of their expanding product pipeline and strategic government contracts like the recent $69 million agreement for influenza treatment RAPIVAB®. These elements collectively highlight BioCryst’s proactive approach in addressing critical unmet medical needs while positioning itself for robust future growth.

• Get an in-depth perspective on BioCryst Pharmaceuticals' performance by reading our health report here.

• Examine BioCryst Pharmaceuticals' past performance report to understand how it has performed in the past.

Seize The Opportunity

• Access the full spectrum of 250 US High Growth Tech and AI Stocks by clicking on this link.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:GDS NasdaqGS:ALKT and NasdaqGS:BCRX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com